News & Updates
Filter by Specialty:
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.
Atezolizumab-bevacizumab combo trumps sorafenib for advanced HCC
27 Mar 2022
Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.
Polymeric immunoglobulin receptor boosts cancer stemness, tumorigenesis in HCC patients
26 Mar 2022
IV steroids may do more harm than good in older-onset ulcerative colitis
In patients with older-onset ulcerative colitis (UC), treatment with intravenous (IV) steroids appears to be less effective and is associated with higher risks of surgery and adverse events relative to patients with younger-onset disease, a study has found.
IV steroids may do more harm than good in older-onset ulcerative colitis
26 Mar 2022
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
A moderate increase in the consumption of foods rich in isoflavone can help reduce the risk of lung cancer in women with no smoking history, suggests a study.
Moderate intake of dietary isoflavone lowers lung cancer risk in nonsmoking women
26 Mar 2022
TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.